• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

I型γ磷脂酰肌醇磷酸激酶通过激活核因子κB来调节程序性死亡受体配体1的表达。

Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB.

作者信息

Xue Junli, Chen Chunhua, Qi Manlong, Huang Yan, Wang Lin, Gao Yong, Dong Haidong, Ling Kun

机构信息

Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.

Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55902, USA.

出版信息

Oncotarget. 2017 Jun 27;8(26):42414-42427. doi: 10.18632/oncotarget.17123.

DOI:10.18632/oncotarget.17123
PMID:28465490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5522076/
Abstract

The programmed death-ligand 1 (PD-L1), by binding to PD-1 on the surface of immune cells, activates a major immune checkpoint pathway. Elevated expression of PD-L1 in tumor cells mediates tumor-induced T-cell exhaustion and immune suppression; therefore protect the survival of tumor cells. Although blockade of the PD-1/PD-L1 axis exhibits great potential in cancer treatment, mechanisms driving the up-regulation of PD-L1 in tumor cells remain not fully understood. Here we found that type Iγ phosphatidylinositol 4-phosphate (PtdIns(4)P) 5-kinase (PIPKIγ) is required for PD-L1 expression in triple negative breast cancer cells. Depletion of PIPKIγ inhibits both intrinsic and induced PD-L1 expression. Results from further analyses suggest that PIPKIγ promotes the transcription of the PD-L1 gene by activating the NF-κB pathway in these cells. These results demonstrate that PIPKIγ-dependent expression of PD-L1 is likely important for the progression of triple negative breast cancer.

摘要

程序性死亡配体1(PD-L1)通过与免疫细胞表面的PD-1结合,激活主要的免疫检查点通路。肿瘤细胞中PD-L1表达升高介导肿瘤诱导的T细胞耗竭和免疫抑制,从而保护肿瘤细胞的存活。尽管阻断PD-1/PD-L1轴在癌症治疗中显示出巨大潜力,但驱动肿瘤细胞中PD-L1上调的机制仍未完全了解。在此,我们发现Iγ型磷脂酰肌醇4-磷酸(PtdIns(4)P)5-激酶(PIPKIγ)是三阴性乳腺癌细胞中PD-L1表达所必需的。PIPKIγ的缺失抑制了内源性和诱导性PD-L1的表达。进一步分析结果表明,PIPKIγ通过激活这些细胞中的NF-κB途径促进PD-L1基因的转录。这些结果表明,PD-L1的PIPKIγ依赖性表达可能对三阴性乳腺癌的进展很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048f/5522076/66f6b120d381/oncotarget-08-42414-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048f/5522076/66f6b120d381/oncotarget-08-42414-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048f/5522076/66f6b120d381/oncotarget-08-42414-g001.jpg

相似文献

1
Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB.I型γ磷脂酰肌醇磷酸激酶通过激活核因子κB来调节程序性死亡受体配体1的表达。
Oncotarget. 2017 Jun 27;8(26):42414-42427. doi: 10.18632/oncotarget.17123.
2
Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.Syntenin1/MDA-9 (SDCBP) 通过上调 PD-L1 在三阴性乳腺癌中诱导免疫逃逸。
Breast Cancer Res Treat. 2018 Sep;171(2):345-357. doi: 10.1007/s10549-018-4833-8. Epub 2018 May 29.
3
Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.炎性细胞因子白细胞介素-17(IL-17)和肿瘤坏死因子-α(TNF-α)上调人前列腺癌细胞和结肠癌细胞中程序性死亡受体配体1(PD-L1)的表达。
Immunol Lett. 2017 Apr;184:7-14. doi: 10.1016/j.imlet.2017.02.006. Epub 2017 Feb 14.
4
LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation.LPS 通过 NF-κB 激活促进胃癌细胞中 PD-L1 的表达。
J Cell Biochem. 2018 Dec;119(12):9997-10004. doi: 10.1002/jcb.27329. Epub 2018 Aug 26.
5
Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer.靶向Ⅰγ型磷酸肌醇 3-激酶克服结直肠癌的奥沙利铂耐药性。
Theranostics. 2022 May 20;12(9):4386-4398. doi: 10.7150/thno.69863. eCollection 2022.
6
ERα is a negative regulator of PD-L1 gene transcription in breast cancer.ERα 是乳腺癌中 PD-L1 基因转录的负调控因子。
Biochem Biophys Res Commun. 2018 Oct 20;505(1):157-161. doi: 10.1016/j.bbrc.2018.09.005. Epub 2018 Sep 18.
7
Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.芝麻素抑制乳腺癌细胞程序性死亡配体 1(PD-L1)的表达。
Int Immunopharmacol. 2020 Sep;86:106759. doi: 10.1016/j.intimp.2020.106759. Epub 2020 Jul 11.
8
JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.JAK2 和 PD-L1 扩增增强三阴性乳腺癌中 PD-L1 的动态表达。
Clin Breast Cancer. 2018 Oct;18(5):e1205-e1215. doi: 10.1016/j.clbc.2018.05.006. Epub 2018 May 26.
9
PD-L1 expression in triple-negative breast cancer.PD-L1 在三阴性乳腺癌中的表达。
Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10.
10
Targeting type Iγ phosphatidylinositol phosphate kinase inhibits breast cancer metastasis.靶向Iγ型磷脂酰肌醇磷酸激酶可抑制乳腺癌转移。
Oncogene. 2015 Aug 27;34(35):4635-46. doi: 10.1038/onc.2014.393. Epub 2014 Dec 8.

引用本文的文献

1
Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities.癌症中的磷酸肌醇激酶:从分子机制到治疗机遇
Nat Rev Cancer. 2025 Apr 3. doi: 10.1038/s41568-025-00810-1.
2
Multi-Pathway Study for Oxaliplatin Resistance Reduction.降低奥沙利铂耐药性的多途径研究
Curr Issues Mol Biol. 2025 Mar 4;47(3):172. doi: 10.3390/cimb47030172.
3
Pip5k1c expression in osteocytes regulates bone remodeling in mice.骨细胞中Pip5k1c的表达调节小鼠的骨重塑。

本文引用的文献

1
Immune checkpoints in aggressive breast cancer subtypes.侵袭性乳腺癌亚型中的免疫检查点。
Neoplasma. 2016;63(5):768-73. doi: 10.4149/neo_2016_514.
2
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.三阴性乳腺癌中PD-L1表达及CD274基因改变:对预后生物标志物的意义
Springerplus. 2016 Jun 21;5(1):805. doi: 10.1186/s40064-016-2513-x. eCollection 2016.
3
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.基于不同免疫组化抗体的三阴性乳腺癌中PD-L1的表达
J Orthop Translat. 2024 Mar 8;45:36-47. doi: 10.1016/j.jot.2023.10.008. eCollection 2024 Mar.
4
Lipid kinases PIP5Ks and PIP4Ks: potential drug targets for breast cancer.脂质激酶PIP5K和PIP4K:乳腺癌的潜在药物靶点。
Front Oncol. 2023 Dec 13;13:1323897. doi: 10.3389/fonc.2023.1323897. eCollection 2023.
5
The Multifunctional Nature of the MicroRNA/AKT3 Regulatory Axis in Human Cancers.miRNA/AKT3 调控轴在人类癌症中的多功能性。
Cells. 2023 Nov 9;12(22):2594. doi: 10.3390/cells12222594.
6
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.癌症免疫治疗中靶向程序性死亡受体1/程序性死亡配体1:治疗三阴性乳腺癌(TNBC)患者的有效策略。
Genes Dis. 2022 Aug 24;10(4):1318-1350. doi: 10.1016/j.gendis.2022.07.024. eCollection 2023 Jul.
7
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.肿瘤细胞 PD-L1 表达与纳武单抗单药治疗转移性透明细胞肾细胞癌反应的转录组学相关性。
Clin Cancer Res. 2022 Sep 15;28(18):4045-4055. doi: 10.1158/1078-0432.CCR-22-0923.
8
Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer.靶向Ⅰγ型磷酸肌醇 3-激酶克服结直肠癌的奥沙利铂耐药性。
Theranostics. 2022 May 20;12(9):4386-4398. doi: 10.7150/thno.69863. eCollection 2022.
9
Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study.肿瘤微环境异质性与非透明细胞肾细胞癌的临床预后相关:一项单细胞基因组学研究。
Cell Death Dis. 2022 Jan 11;13(1):50. doi: 10.1038/s41419-022-04501-9.
10
NDRG2 Expression in Breast Cancer Cells Downregulates PD-L1 Expression and Restores T Cell Proliferation in Tumor-Coculture.乳腺癌细胞中NDRG2的表达下调程序性死亡受体配体1(PD-L1)的表达并恢复肿瘤共培养体系中T细胞的增殖。
Cancers (Basel). 2021 Dec 4;13(23):6112. doi: 10.3390/cancers13236112.
J Transl Med. 2016 Jun 10;14(1):173. doi: 10.1186/s12967-016-0925-6.
4
Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.程序性死亡配体-1在乳腺癌中的预后及临床病理价值:一项Meta分析
PLoS One. 2016 May 26;11(5):e0156323. doi: 10.1371/journal.pone.0156323. eCollection 2016.
5
PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.程序性死亡受体配体1(PD-L1)表达与乳腺癌肿瘤中叉头框蛋白P3(FOXP3)阳性调节性T细胞浸润及患者预后不良相关。
J Cancer. 2016 Apr 10;7(7):784-93. doi: 10.7150/jca.14549. eCollection 2016.
6
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.乳腺癌脑转移及其微环境中的免疫反应:PD-1/PD-L轴的作用
Breast Cancer Res. 2016 Apr 27;18(1):43. doi: 10.1186/s13058-016-0702-8.
7
ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer proliferation.膜联蛋白A1通过核因子-κB和c-Myc在负反馈回路中抑制微小RNA-196a,以减少乳腺癌增殖。
Oncotarget. 2016 May 10;7(19):27007-20. doi: 10.18632/oncotarget.8875.
8
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.程序性死亡受体配体1(PD-L1)的表达与头颈部鳞状细胞癌的上皮-间质转化相关。
Oncotarget. 2016 Mar 29;7(13):15901-14. doi: 10.18632/oncotarget.7431.
9
Targeting the programmed cell death-1 pathway in breast and ovarian cancer.靶向乳腺癌和卵巢癌中的程序性细胞死亡-1通路。
Curr Opin Obstet Gynecol. 2016 Apr;28(2):142-7. doi: 10.1097/GCO.0000000000000257.
10
PKD signaling and pancreatitis.多囊肾病信号传导与胰腺炎
J Gastroenterol. 2016 Jul;51(7):651-9. doi: 10.1007/s00535-016-1175-3. Epub 2016 Feb 15.